Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4

Cell Biochemistry and Function

Volumn 31, Issue 7, 2013, Pages 620-625

  Shaker, Olfat ^a   El Shehaby, Amal ^a   Fayez, Salwa ^a   Zahra, Amr ^b   Marzouk, Samar ^a   El Raziky, Maissa ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b FAYOUM UNIVERSITY   (Egypt)

Author keywords

Hepatitis C; Osteopontin; Polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FETOPROTEIN; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; OSTEOPONTIN; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

HEPATITIS C; OSTEOPONTIN; POLYMORPHISM;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; EGYPT; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OSTEOPONTIN; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84884982814     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2954     Document Type: Article

References (30)

1. World Health Organization. Initiative for vaccine research. Hepatitis C. (2010). (Accessed February 8, 2010, http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.)
2. Barrera LM, Bruguera M, Ercilla MG, Gil C, Celis C, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-644.
3. Amoroso P, Rapicetta M, Tosti ME, Mele A, Spada E, Buonocore S, et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. Hepatol 1998; 28: 939-944.
4. Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. J Gastroenterol Hepatol 2000; 15: E97-E104.
5. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
6. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
7. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131: 174-181.
8. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peg interferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361(6): 580-593.
9. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009; 52: 301-309.
10. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686-1695.
11. Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81: 640-649.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
13. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
14. Romero-Gomez M, Del Mar VM, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
15. El Makhzangy H, Esmat G, Said M, ElRaziky M, Shouman S, Refai R, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009; 81(9): 1576-1583.
16. Halfon P, Bourliére M, Ouzan D, Renou C, Wartelle C, Pénaranda G, et al. IL-28 gene variation predicts who will respond to interferon-based treatment of chronic hepatitis C in a French cohort. J Hepatol 2010; 52: 319-457.
17. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-388.
18. Uede T, Katagiri Y, Iizuka J, Murakami M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol Immunol 1997; 41: 641-648.
19. Kawashima R, Mochida S, Matsui A, Youlutuz Y, Ishikawa K, Toshima K, et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999; 256: 527-531.
20. Wang Y, Mochida S, Kawashima R, Inao M, Matsui A, Youlutuz Y, et al. Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver. J Gastroenterol 2000; 35: 696-701.
21. Ashkar A, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
22. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993; 13: 225-246.
23. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta 2010; 411: 675-678.
24. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
25. Mochida S, Hashimoto M, Matsui A, Naito V, Inao M, Nagoshi S, et al. Genetic polymorphisms in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004; 313: 1079-1085.
26. Yamamoto S, Hijiya N, Setoguchi M, Matsuura K, Ishida T, Higuchi Y, et al. Structure of the osteopontin gene and its promoter. Ann N Y Acad Sci 1995; 760: 44-58.
27. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-107.
28. Lee SH, Seo GS, Park YN, Yoo TM, Sohn DH. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004; 68: 2367-2378.
29. Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 2007; 24: 93-146.
30. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345.